Asthma Treatment
Asthma Treatment
Treatment of asthma is organised around two arms that do different jobs. One opens the airway within minutes and is used when symptoms occur; the other treats the inflammation underneath and is taken when nothing is happening at all. Almost every mistake in asthma treatment comes from confusing the two — usually by leaning on the first and neglecting the second. This page sets out what each arm contains, why the device matters as much as the drug, and how stepping up and stepping down are decided.
Two arms of treatment, and why they are not interchangeable
The reliever is a short-acting bronchodilator that relaxes the muscle wrapped around the airway. It works within minutes and lasts a few hours. Its job is to undo narrowing that has already happened; it does nothing to the inflammation producing that narrowing.
The controller — usually an inhaled corticosteroid — reduces the inflammation in the airway lining. It produces no sensation at all, which is precisely why people reasonably conclude that it does nothing. Its effect accumulates over weeks, and it prevents narrowing rather than treating it.
| Reliever | Controller | |
|---|---|---|
| What it does | Relaxes the muscle around the airway | Reduces the inflammation in the lining |
| How fast it acts | Minutes | Weeks |
| When it is taken | When symptoms occur | Regularly, including on days with no symptoms |
| If it is stopped | Symptoms return within hours | Nothing changes at first, then control is lost over weeks |
| Does it treat the disease? | No — it treats the moment | Yes — this is the treatment |
The consequence is the reliever-only pattern, worth naming because it feels rational at every step. The reliever works immediately, so it feels like treatment. Its use creeping up reads as "my asthma needs more reliever" rather than "my asthma is not controlled". The inflammation continues, the airway becomes more reactive, and the reliever needed rises again.
A practical rule follows. If you are reaching for your reliever more than twice a week, outside doses taken before exercise, that is a signal to review the controller — not to buy more reliever.
Inhaled steroids — the treatment that changed asthma
Inhaled corticosteroids are the most effective controller treatment available for asthma, and they work at doses that are small because the drug is delivered directly to the tissue that is inflamed rather than distributed through the body first.
The fear of the word "steroid" is the largest avoidable obstacle to control. Inhaled steroids are not the oral steroids associated with weight gain, mood change, diabetes and bone loss — those effects are dose-dependent and duration-dependent, and the fraction of an inhaled dose reaching the rest of the body is far smaller. The risks that do belong to inhaled treatment are local and manageable: thrush and hoarseness, prevented by rinsing the mouth after each dose and by using a spacer with a metered-dose inhaler.
The dose is set for the step you are on and reviewed rather than left indefinitely. Growth is monitored in children on inhaled steroids, which is how the reassuring position is kept honest. And the add-ons exist so that the steroid dose does not have to keep rising — a long-acting bronchodilator, a leukotriene receptor antagonist, a long-acting muscarinic antagonist, or theophylline in a limited role.
In some regimens one inhaler contains both the steroid and a long-acting bronchodilator and is used for maintenance and, when needed, as reliever as well. That suits some people and not others; it is a decision for a specific person rather than a general upgrade. Oral steroids are for attacks: a short course during an exacerbation is standard, while continuous oral steroid use for asthma is a sign that the regimen needs rethinking rather than extending.
The device is part of the treatment
A drug that does not reach the airway has not been given. That is not a slogan; it is the reason a correctly chosen treatment can fail completely, and it is one of the commonest reasons a person is described as having difficult asthma when what they have is a device problem.
The errors are consistent and therefore predictable: not shaking a metered-dose inhaler, not priming a new one, pressing and breathing in at the wrong moment, breathing too fast through a dry powder device that needs a quick deep breath or too fast through a spacer that needs a slow one, not holding the breath afterwards, not rinsing the mouth, and using a device that is empty without knowing because some do not rattle.
What fixes it is not more explanation, it is observation. Technique watched rather than described, at every visit, by someone who knows that specific device. A spacer with a metered-dose inhaler, which improves delivery and reduces how much of the drug lands in the mouth. And a device chosen to suit the person using it rather than the one that happens to be in stock — a device that cannot be used properly is simply not a treatment.
One caution about switching. Changing someone from one device to another without teaching the new one is a reliable way to turn a stable patient into an unstable one. If the device changes, the technique should be taught and checked on the new one.
Stepping up and stepping down
Treatment is organised in steps, from a reliever alone at the lightest to high-dose combination treatment with add-ons at the heaviest. Both directions have rules, and both rules exist because both directions can do harm.
Before stepping up, three things are checked — because each of them mimics a need for more drug. Technique: is the drug reaching the airway? Adherence: is it being taken, on the good days as well as the bad? Triggers: has something changed, such as a new pet, a season, a move, a workplace exposure, or an untreated blocked nose? If all three have been addressed and control is still incomplete, stepping up is reasonable rather than reflexive.
Stepping down follows a different rule. Not when you feel well, but after a sustained period of good control — usually several months — and one change at a time, so that any loss of control can be attributed to something rather than to everything. Reducing treatment is worth doing, because every drug carries a cost, but it is done deliberately rather than by drifting.
Severity is defined by this process rather than by symptoms. Severe asthma means asthma requiring high-intensity treatment to stay controlled, or remaining uncontrolled despite it. That is why the label cannot be applied at a first consultation, and why it should be revisited each time the step changes.
How often the step is reviewed, and what is measured each time, is recorded in the plan, so that the interval is a decision rather than a habit. Each review repeats the same short set — pulmonary function testing or a peak flow reading, the four control questions, and a watched check of your inhaler technique — and it is our respiratory and critical care medicine department that carries out the testing and holds the record.
Acute attacks — what treatment does
At home, treatment of an attack follows the written plan: the reliever, taken through a spacer if a metered-dose inhaler is used, repeated at the interval the plan states, with the yellow and red thresholds acted on rather than watched. Waiting to see whether it works one more time is the commonest error, and it is the one a plan exists to remove.
In an emergency setting the treatment follows a standard sequence: oxygen to a target, repeated bronchodilator, an early systemic corticosteroid, and close observation, with additional treatment for a severe attack. The detail is not something a patient needs to memorise; the point is that a severe attack requires treatments no one can give themselves at home, which is why recognising it early matters more than managing it locally.
The part most often missed is what comes after. An attack is evidence that control failed somewhere, and the review that follows is where the next one is prevented: was technique the problem, was adherence, was there a new trigger, was the controller step too low, and does the person hold a written plan. An attack followed by nothing but a discharge is a missed opportunity, and missed opportunities repeat.
Arriving at the hospital shifts treatment to what cannot be done at home. Our respiratory and critical care medicine department manages the acute phase — a repeated bronchodilator, a systemic corticosteroid, oxygen, and mechanical ventilation where the attack is severe — and whether you are observed, admitted or stepped down follows the response to those treatments rather than the presentation. The review before discharge is where the next attack is prevented, and it is arranged by the same department alongside the dedicated lung disease clinic in traditional Chinese medicine.
What the review afterwards should contain — and what should be written down before you leave — is set out on the living-with-it page.
Biologics and the other add-ons
When inhaled treatment has been optimised and control is still poor, add-on treatment is considered. The older add-ons are additional inhalers or tablets — a leukotriene receptor antagonist, a long-acting muscarinic antagonist, theophylline in a limited role. Each has a place, and each has a reason it is not used first.
Biologics are injected treatments that target a specific step in the inflammatory pathway. Choosing between them is not a matter of potency; it is a matter of which inflammation a person has. Allergic asthma with a raised IgE, eosinophilic asthma, and asthma driven by particular signalling molecules each point towards a different option, and the choice is made from the combination of history, blood counts and inflammatory markers rather than from how severe the symptoms feel.
Allergen immunotherapy is different again. Given over years to selected people with clearly allergic asthma, it aims to change the response to a specific allergen rather than suppress inflammation generally. It is not a cure, it does not replace inhaled treatment, and its suitability depends on which allergens are involved, how well the asthma is controlled, and other medical factors.
Two qualifications belong here. Availability and eligibility differ between countries, so what is possible where you are is a practical question rather than a scientific one. And none of these is a reason to reduce the inhaled treatment that is keeping the airway quiet. Which suits a particular person, and whether any is appropriate at all, is a clinical decision made with the full picture.
Living well on treatment
Most of what determines control happens between appointments, and the habits that matter are unglamorous: taking the controller on the days you feel well, using the device the way you were taught, keeping the reliever with you, and acting on the plan when the signs appear rather than when they become undeniable.
A short list of things that genuinely change control. Stop smoking and avoid second-hand smoke, which worsens asthma independently of everything else here. Keep vaccinations current according to your team's advice, because respiratory infections commonly trigger attacks. Treat rhinitis, reflux and obstructive sleep apnoea rather than putting up with them, since each worsens control and each has its own treatment. Address weight where it applies. And avoid the triggers that reliably provoke symptoms without organising your life around avoidance — the goal is a normal life with fewer triggers, not a smaller one.
Exercise sits in the same category. It is part of treatment rather than an exception to it, and the target is doing what you want without symptoms. Symptoms on exertion are a reason to review the treatment, not a reason to stop.
Pregnancy deserves a line of its own, because the instinct to stop medication is the wrong one here. Poorly controlled asthma is the risk to the pregnancy; the inhaled treatment is generally the safer option, and it is continued and reviewed rather than withdrawn. That decision is made with the clinical team, in advance where possible.